Instrument Inactif

Autres langues Spark Therapeutics, Inc.

Actions

US84652J1034

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	14/10/23
One of Nature’s journals publishes article about CombiGene’s epilepsy project	11/04/23
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	30/01/23
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	30/01/23
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	27/01/23
Roche: Gentherapie SPK-8011 von Tochter Spark erweist sich als dauerhaft wirksam	12/12/22
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	12/12/22
Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	17/05/22
CombiGene presents at Aktiedagen Göteborg on Monday 16 May	10/05/22
BioStock: CombiGene strives for a broader pipeline	21/04/22
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	23/02/22
CombiGene launches new website	21/02/22
Year-end report January-December 2021 CombiGene AB (Publ)	17/02/22
BioStock: CombiGene's CEO gives business development update	11/02/22
CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution	08/02/22
GMP production of CG01 made available for preclinical studies planned to enable First in Human study	17/01/22
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel's University City Campus	20/12/21
BioStock: CombiGene's CEO about the path to the first clinical trial	20/12/21
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe	16/12/21
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	16/12/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Spark Therapeutics, Inc.

Actions

US84652J1034

Autres langues

Filtres